Aptar's Intranasal Technology to Be Used for Milestone's FDA-Approved Heart Treatment

Dow Jones

2025/12/18

By Elias Schisgall

Aptar Group said its intranasal medical delivery technology will be used to administer Cardamyst, a treatment for paroxysmal supraventricular tachycardia in adults.

The consumer technology company said Wednesday that its Bidose Liquid Nasal Spray System would be the mechanism to deliver Cardamyst, a drug developed by Milestone Pharmaceuticals to treat symptoms of PSVT, a condition that causes a sudden elevated heart rate.

Cardamyst received Food and Drug Administration approval last week.

Aptar Group said it collaborated with Milestone to build a custom delivery system with a fully integrated cap for Cardamyst, designed to prevent accidental activation or other user errors.

"This approval underscores the broadening of Aptar's drug delivery solutions for more therapeutic areas and the growing demand for nasal drug delivery," Aptar Pharma President Gael Touya said. "We are pleased that our trusted and proven Bidose nasal system, combined with our protective dual-container system, is now available for patients in yet another therapeutic area."

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

December 17, 2025 17:26 ET (22:26 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2592946247"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2592946247\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2592946247?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 06:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592946247","market":"sh","top_or_hot":-1,"title":"Aptar's Intranasal Technology to Be Used for Milestone's FDA-Approved Heart Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ATR\">Aptar</a> Group said its intranasal medical delivery technology will be used to administer Cardamyst, a treatment for paroxysmal supraventricular tachycardia in adults. \n</p>\n<p>\n  The consumer technology company said Wednesday that its Bidose Liquid Nasal Spray System would be the mechanism to deliver Cardamyst, a drug developed by Milestone Pharmaceuticals to treat symptoms of PSVT, a condition that causes a sudden elevated heart rate. \n</p>\n<p>\n  Cardamyst received Food and Drug Administration approval last week. \n</p>\n<p>\n  Aptar Group said it collaborated with Milestone to build a custom delivery system with a fully integrated cap for Cardamyst, designed to prevent accidental activation or other user errors. \n</p>\n<p>\n  \"This approval underscores the broadening of Aptar's drug delivery solutions for more therapeutic areas and the growing demand for nasal drug delivery,\" Aptar Pharma President Gael Touya said. \"We are pleased that our trusted and proven Bidose nasal system, combined with our protective dual-container system, is now available for patients in yet another therapeutic area.\" \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 17, 2025 17:26 ET (22:26 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aptar's Intranasal Technology to Be Used for Milestone's FDA-Approved Heart Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAptar's Intranasal Technology to Be Used for Milestone's FDA-Approved Heart Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-18 06:26</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ATR\">Aptar</a> Group said its intranasal medical delivery technology will be used to administer Cardamyst, a treatment for paroxysmal supraventricular tachycardia in adults. \n</p>\n<p>\n  The consumer technology company said Wednesday that its Bidose Liquid Nasal Spray System would be the mechanism to deliver Cardamyst, a drug developed by Milestone Pharmaceuticals to treat symptoms of PSVT, a condition that causes a sudden elevated heart rate. \n</p>\n<p>\n  Cardamyst received Food and Drug Administration approval last week. \n</p>\n<p>\n  Aptar Group said it collaborated with Milestone to build a custom delivery system with a fully integrated cap for Cardamyst, designed to prevent accidental activation or other user errors. \n</p>\n<p>\n  \"This approval underscores the broadening of Aptar's drug delivery solutions for more therapeutic areas and the growing demand for nasal drug delivery,\" Aptar Pharma President Gael Touya said. \"We are pleased that our trusted and proven Bidose nasal system, combined with our protective dual-container system, is now available for patients in yet another therapeutic area.\" \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 17, 2025 17:26 ET (22:26 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4126","symbol_name":"金属与玻璃容器","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2592946247","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592946247","pubTimestamp":1766010360,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Aptar Group said its intranasal medical delivery technology will be used to administer Cardamyst, a treatment for paroxysmal supraventricular tachycardia in adults.The consumer technology company said Wednesday that its Bidose Liquid Nasal Spray System would be the mechanism to deliver Cardamyst, a drug developed by Milestone Pharmaceuticals to treat symptoms of PSVT, a condition that causes a sudden elevated heart rate.Cardamyst received Food and Drug Administration approval last week.Aptar Group said it collaborated with Milestone to build a custom delivery system with a fully integrated cap for Cardamyst, designed to prevent accidental activation or other user errors.\"This approval underscores the broadening of Aptar's drug delivery solutions for more therapeutic areas and the growing demand for nasal drug delivery,\" Aptar Pharma President Gael Touya said. \"We are pleased that our trusted and proven Bidose nasal system, combined with our protective dual-container system, is now avai","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4126":"金属与玻璃容器","ATR":"Aptar"},"translate_title":"Aptar的鼻内技术将用于Milestone获得FDA批准的心脏治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATR":0.9},"content_text":"By Elias Schisgall \n\n\n \n\n\nAptar Group said its intranasal medical delivery technology will be used to administer Cardamyst, a treatment for paroxysmal supraventricular tachycardia in adults. \n\n\n  The consumer technology company said Wednesday that its Bidose Liquid Nasal Spray System would be the mechanism to deliver Cardamyst, a drug developed by Milestone Pharmaceuticals to treat symptoms of PSVT, a condition that causes a sudden elevated heart rate. \n\n\n  Cardamyst received Food and Drug Administration approval last week. \n\n\n  Aptar Group said it collaborated with Milestone to build a custom delivery system with a fully integrated cap for Cardamyst, designed to prevent accidental activation or other user errors. \n\n\n  \"This approval underscores the broadening of Aptar's drug delivery solutions for more therapeutic areas and the growing demand for nasal drug delivery,\" Aptar Pharma President Gael Touya said. \"We are pleased that our trusted and proven Bidose nasal system, combined with our protective dual-container system, is now available for patients in yet another therapeutic area.\" \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 17, 2025 17:26 ET (22:26 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}